Magnetic Resonance Spectroscopy: Tools for Neuroscience Research and Emerging Clinical Applications

[1]  T. Saheki,et al.  Reduced N-Acetylaspartate Levels in Mice Lacking Aralar, a Brain- and Muscle-type Mitochondrial Aspartate-glutamate Carrier* , 2005, Journal of Biological Chemistry.

[2]  M. Baslow,et al.  Evidence supporting a role for N-acetyl-l-aspartate as a molecular water pump in myelinated neurons in the central nervous system An analytical review , 2002, Neurochemistry International.

[3]  J. MacDonald,et al.  Epigenetic regulation of nervous system development by DNA methylation and histone deacetylation , 2009, Progress in Neurobiology.

[4]  D. Shera,et al.  Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. , 2002, Human gene therapy.

[5]  D. Hampson,et al.  The Neuroactive Peptide N-Acetylaspartylglutamate Is Not an Agonist at the Metabotropic Glutamate Receptor Subtype 3 of Metabotropic Glutamate Receptor , 2009, Journal of Pharmacology and Experimental Therapeutics.

[6]  T. Saheki,et al.  Deficiency of the mitochondrial transporter of aspartate/glutamate aralar/AGC1 causes hypomyelination and neuronal defects unrelated to myelin deficits in mouse brain , 2011, Journal of Neuroscience Research.

[7]  F. Orrego,et al.  A study of possible excitatory effects of N-acetylaspartylglutamate in different in vivo and in vitro brain preparations , 1984, Brain Research.

[8]  A. Minagar,et al.  Role of magnetic resonance spectroscopy in diagnosis and management of multiple sclerosis , 2006, Neurological research.

[9]  M. Brownstein,et al.  N‐Acetylation of L‐Aspartate in the Nervous System: Differential Distribution of a Specific Enzyme , 1985, Journal of neurochemistry.

[10]  R. Kaul,et al.  Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease. , 1996, American journal of human genetics.

[11]  H. Lindner,et al.  The distribution of aminoacylase I among mammalian species and localization of the enzyme in porcine kidney. , 2000, Biochimie.

[12]  J. de Vellis,et al.  Capacity for substrate utilization in oxidative metabolism by neurons, astrocytes, and oligodendrocytes from developing brain in primary culture , 1987, Journal of neuroscience research.

[13]  J. Coyle,et al.  Distribution of N-acetylaspartylglutamate immunoreactivity in human brain and its alteration in neurodegenerative disease , 1997, Brain Research.

[14]  R. Ledeen.  Lipid-metabolizing enzymes of myelin and their relation to the axon. , 1984, Journal of lipid research.

[15]  J. Moffett,et al.  Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease , 2010, Journal of Inherited Metabolic Disease.

[16]  Giuseppe Lazzarino,et al.  The Pathophysiology of Concussion , 2011, PM & R : the journal of injury, function, and rehabilitation.

[17]  S. Tieman.  Cellular localization of NAAG. , 2006, Advances in experimental medicine and biology.

[18]  E. Moser,et al.  1H magnetic resonance spectroscopy at 3 T in cryptogenic and mesial temporal lobe epilepsy , 2006, NMR in biomedicine.

[19]  S. Blüml,et al.  Direct determination of the N‐acetyl‐l‐aspartate synthesis rate in the human brain by 13C MRS and [1‐13C]glucose infusion , 2001, Journal of neurochemistry.

[20]  J. Neale.  N‐Acetylaspartylglutamate is an agonist at mGluR3 in vivo and in vitro , 2011, Journal of neurochemistry.

[21]  J. Moffett,et al.  Antipsychotic drugs increase N‐acetylaspartate and N‐acetylaspartylglutamate in SH‐SY5Y human neuroblastoma cells , 2008, Journal of neurochemistry.

[22]  S. Leucht,et al.  Proton Magnetic Resonance Spectroscopy and Illness Stage in Schizophrenia—A Systematic Review and Meta-Analysis , 2011, Biological Psychiatry.

[23]  M. Baslow.  Hypothesis: Molecular water pumps and the aetiology of Canavan disease: A case of the sorcerer's apprentice , 1999, Journal of Inherited Metabolic Disease.

[24]  Caixia Hu,et al.  Stimulation-Induced Decreases in the Diffusion of Extra-vascular Water in the Human Visual Cortex: a Window in Time and Space on Mechanisms of Brain Water Transport and Economy , 2012, Journal of Molecular Neuroscience.

[25]  J. Neale,et al.  Biosynthesis of NAAG by an enzyme‐mediated process in rat central nervous system neurons and glia , 2004, Journal of neurochemistry.

[26]  P. Bajpai,et al.  Bimodal targeting of cytochrome P450s to endoplasmic reticulum and mitochondria: the concept of chimeric signals , 2011, The FEBS journal.

[27]  R. Matalon,et al.  Molecular basis of Canavan disease. , 1998, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[28]  C. N. Madhavarao,et al.  Characterization of the N‐acetylaspartate biosynthetic enzyme from rat brain , 2003, Journal of neurochemistry.

[29]  P. Conn,et al.  Metabotropic glutamate receptors: physiology, pharmacology, and disease. , 2010, Annual review of pharmacology and toxicology.

[30]  T. Tsukamoto,et al.  Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. , 2007, Drug discovery today.

[31]  J. Moffett,et al.  Evidence for mitochondrial and cytoplasmic N-acetylaspartate synthesis in SH-SY5Y neuroblastoma cells , 2009, Neurochemistry International.

[32]  S. Tieman,et al.  N-acetylaspartylglutamate immunoreactivity in human retina , 1996, Vision Research.

[33]  I. Marshall,et al.  Studies of acute ischemic stroke with proton magnetic resonance spectroscopy: relation between time from onset, neurological deficit, metabolite abnormalities in the infarct, blood flow, and clinical outcome. , 1998, Stroke.

[34]  R. Matalon,et al.  Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. , 1988, American journal of medical genetics.

[35]  D. Jacobowitz,et al.  Immunohistochemical localization of aspartoacylase in the rat central nervous system , 2004, The Journal of comparative neurology.

[36]  Yuko Fujita,et al.  Orally active glutamate carboxypeptidase II inhibitor 2-MPPA attenuates dizocilpine-induced prepulse inhibition deficits in mice , 2011, Brain Research.

[37]  F. J. Ballard.  Supply and utilization of acetate in mammals. , 1972, The American journal of clinical nutrition.

[38]  I. Akiguchi,et al.  Absolute Quantification in Proton Magnetic Resonance Spectroscopy Is Useful to Differentiate Amnesic Mild Cognitive Impairment from Alzheimer’s Disease and Healthy Aging , 2010, Dementia and Geriatric Cognitive Disorders.

[39]  M. Rollag,et al.  Murine aspartoacylase: cloning, expression and comparison with the human enzyme. , 2000, Brain research. Molecular brain research.

[40]  M. Palkovits,et al.  N-acetylaspartylglutamate: a transmitter candidate for the retinohypothalamic tract. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Matalon,et al.  Aspartoacylase gene knockout results in severe vacuolation in the white matter and gray matter of the spinal cord in the mouse , 2005, Neurobiology of Disease.

[42]  J. Moffett,et al.  Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[43]  T. Serikawa,et al.  Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[44]  J. Neale,et al.  Immunohistochemistry and Biosynthesis of N‐Acetylaspartylglutamate in Spinal Sensory Ganglia , 1987, Journal of neurochemistry.

[45]  R. Kaul,et al.  Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease , 1993, Nature genetics.

[46]  T. Salt,et al.  The effects of N-acetylaspartylglutamate and distribution of N-acetylaspartylglutamate-like immunoreactivity in the rat somatosensory thalamus , 1988, Neuroscience.

[47]  R. Matalon,et al.  Bimodal occurrence of aspartoacylase in myelin and cytosol of brain , 2007, Journal of neurochemistry.

[48]  F. Nicoletti,et al.  Metabotropic glutamate receptors: From the workbench to the bedside , 2011, Neuropharmacology.

[49]  A. Sima,et al.  GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats , 2002, Journal of the Neurological Sciences.

[50]  F. Goldstein.  Biosynthesis of N-acetyl-L-aspartic acid. , 1959, Biochimica et biophysica acta.

[51]  F. Goldstein.  The enzymatic synthesis of N-acetyl-L-aspartic acid by subcellular preparations of rat brain. , 1969, The Journal of biological chemistry.

[52]  W. Danysz,et al.  Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain – relation to brain concentration , 2006, Neuropharmacology.

[53]  J. de Vellis,et al.  Canavan disease: a white matter disorder. , 2006, Mental retardation and developmental disabilities research reviews.

[54]  L Symon,et al.  Investigation into the Role of N‐Acetylaspartate in Cerebral Osmoregulation , 1995, Journal of neurochemistry.

[55]  M. Mayer,et al.  High concentrations of N-acetylaspartylglutamate (NAAG) selectively activate NMDA receptors on mouse spinal cord neurons in cell culture , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[56]  R. Matalon,et al.  Does ASPA gene mutation in Canavan disease alter oligodendrocyte development? A tissue culture study of ASPA KO mice brain. , 2006, Advances in experimental medicine and biology.

[57]  D. Jacobowitz,et al.  Nuclear‐cytoplasmic localization of acetyl coenzyme a synthetase‐1 in the rat brain , 2010, The Journal of comparative neurology.

[58]  SH-SY5Y neuroblastoma cells: a model system for studying biosynthesis of NAAG , 2004, Neuroreport.

[59]  J. Clark,et al.  N-Acetyl Aspartate: A Marker for Neuronal Loss or Mitochondrial Dysfunction , 1998, Developmental Neuroscience.

[60]  M. S. Leaning,et al.  Analytical Review , 2020, 1789.

[61]  J. Babb,et al.  Longitudinal Whole-Brain N-Acetylaspartate Concentration in Healthy Adults , 2011, American Journal of Neuroradiology.

[62]  J. Coyle,et al.  Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies , 1991, Neuroscience.

[63]  Roberto Sorge,et al.  Assessment of metabolic brain damage and recovery following mild traumatic brain injury: a multicentre, proton magnetic resonance spectroscopic study in concussed patients. , 2010, Brain : a journal of neurology.

[64]  L. Hagenfeldt,et al.  N-acetylaspartic aciduria due to aspartoacylase deficiency — a new aetiology of childhood leukodystrophy , 1987, Journal of Inherited Metabolic Disease.

[65]  R. Gruetter,et al.  Dynamic or inert metabolism? Turnover of N‐acetyl aspartate and glutathione from d‐[1‐13C]glucose in the rat brain in vivo , 2004, Journal of neurochemistry.

[66]  J. Cooper,et al.  N‐ACETYL‐l‐ASPARTIC ACID CONTENT OF HUMAN NEURAL TUMOURS AND BOVINE PERIPHERAL NERVOUS TISSUES , 1972, Journal of neurochemistry.

[67]  H. Tallan,et al.  N-Acetyl-L-aspartic acid in brain. , 1956, The Journal of biological chemistry.

[68]  J. Kew,et al.  Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR , 2009, Neuropharmacology.

[69]  J. Neale,et al.  NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia , 2012, Translational Psychiatry.

[70]  D. Jacobowitz,et al.  Extensive aspartoacylase expression in the rat central nervous system , 2011, Glia.

[71]  J. Coyle,et al.  N-Acetylaspartate in neuropsychiatric disorders , 1995, Progress in Neurobiology.

[72]  E. Kvamme,et al.  ACETYLATED AND PEPTIDE BOUND GLUTAMATE AND ASPARTATE IN BRAIN , 1967, Journal of neurochemistry.

[73]  F. Sterky,et al.  AGC1 deficiency associated with global cerebral hypomyelination. , 2009, The New England journal of medicine.

[74]  Morris H. Baslow,et al.  Brain N-acetylaspartate as a molecular water pump and its role in the etiology of canavan disease , 2007, Journal of Molecular Neuroscience.

[75]  E. Miyamoto,et al.  IDENTIFICATION OF N‐ACETYL‐α‐ASPARTYLGLUTAMIC ACID IN THE BOVINE BRAIN , 1966 .

[76]  B. Slusher,et al.  The role of glutamate signaling in pain processes and its regulation by GCP II inhibition. , 2012, Current medicinal chemistry.

[77]  T. Patel,et al.  Synthesis of N-acetyl-L-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. , 1979, The Biochemical journal.

[78]  J. Rothstein,et al.  NAALADase inhibition protects motor neurons against chronic glutamate toxicity. , 2003, European journal of pharmacology.

[79]  W. Heindel,et al.  Quantitative measurements with localized 1H MR spectroscopy in children with Canavan's disease , 1996, Journal of magnetic resonance imaging : JMRI.

[80]  A. Gass,et al.  Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients’ assessment , 2012, Multiple sclerosis.

[81]  J. Neale,et al.  Immunohistochemical localization of N-acetylaspartate in rat brain. , 1991, Neuroreport.

[82]  P. Leone,et al.  Aspartoacylase Supports Oxidative Energy Metabolism during Myelination , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[83]  C. Corti,et al.  The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity , 2008, Psychopharmacology.

[84]  C. Cotman,et al.  N-Acetylaspartylglutamate identified in the rat retinal ganglion cells and their projections in the brain , 1987, Brain Research.

[85]  R. Kaul,et al.  Canavan disease: mutations among Jewish and non-Jewish patients. , 1994, American journal of human genetics.

[86]  J. Coyle,et al.  N-Acetylaspartylglutamate: possible role as the neurotransmitter of the lateral olfactory tract. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[87]  J. Coyle,et al.  Hydrolysis of the neuropeptide N-acetylaspartylglutamate (NAAG) by cloned human glutamate carboxypeptidase II 1 Published on the World Wide Web on 24 April 1998. 1 , 1998, Brain Research.

[88]  L. Puglielli,et al.  A reversible form of lysine acetylation in the ER and Golgi lumen controls the molecular stabilization of BACE1. , 2007, The Biochemical journal.

[89]  J. Neale,et al.  Uptake, Metabolism, and Release of N‐[3H]‐Acetylaspartylglutamate by the Avian Retina , 1992, Journal of neurochemistry.

[90]  I Savic,et al.  MR Spectroscopy Shows Reduced Frontal Lobe Concentrations of N‐Acetyl Aspartate in Patients with Juvenile Myoclonic Epilepsy , 2000, Epilepsia.

[91]  P. Casaccia‐Bonnefil,et al.  Epigenetic mechanisms facilitating oligodendrocyte development, maturation, and aging , 2009, Glia.

[92]  Stephanie Spange,et al.  Acetylation of non-histone proteins modulates cellular signalling at multiple levels. , 2009, The international journal of biochemistry & cell biology.

[93]  J. Neale,et al.  Enhanced carbodiimide fixation for immunohistochemistry: application to the comparative distributions of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat brain. , 1993, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[94]  J. Neale,et al.  N‐Acetylaspartylglutamate Inhibits Forskolin‐Stimulated Cyclic AMP Levels via a Metabotropic Glutamate Receptor in Cultured Cerebellar Granule Cells , 1993, Journal of neurochemistry.

[95]  J. Coyle,et al.  Co‐localization of N‐acetyl‐aspartyl‐glutamate in central cholinergic, noradrenergic, and serotonergic neurons , 1987, Synapse.

[96]  B. Barres,et al.  Nur7 Is a Nonsense Mutation in the Mouse Aspartoacylase Gene That Causes Spongy Degeneration of the CNS , 2008, The Journal of Neuroscience.

[97]  J. Neale,et al.  Effects of N-Acetylaspartylglutamate (NAAG) Peptidase Inhibition on Release of Glutamate and Dopamine in Prefrontal Cortex and Nucleus Accumbens in Phencyclidine Model of Schizophrenia* , 2012, The Journal of Biological Chemistry.

[98]  J. Verbalis.  Control of brain volume during hypoosmolality and hyperosmolality. , 2006, Advances in experimental medicine and biology.

[99]  R. Matalon,et al.  Lack of aspartoacylase activity disrupts survival and differentiation of neural progenitors and oligodendrocytes in a mouse model of Canavan disease , 2009, Journal of neuroscience research.

[100]  Justin R. Cross,et al.  ATP-Citrate Lyase Links Cellular Metabolism to Histone Acetylation , 2009, Science.

[101]  F. Opperdoes,et al.  Molecular Identification of N-Acetylaspartylglutamate Synthase and β-Citrylglutamate Synthase* , 2010, The Journal of Biological Chemistry.

[102]  R. Kaul,et al.  Canavan disease: genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution. , 1994, Genomics.

[103]  M. Miyake,et al.  Developmental Changes of N‐Acetyl‐L‐Aspartic Acid, N‐Acetyl‐α‐Aspartylglutamic Acid and β‐Citryl‐L‐Glutamic Acid in Different Brain Regions and Spinal Cords of Rat and Guinea Pig , 1981, Journal of neurochemistry.

[104]  A. Durand,et al.  Catabolism of intracellular N-terminal acetylated proteins: involvement of acylpeptide hydrolase and acylase. , 2005, Biochimie.

[105]  Erik A Sistermans,et al.  Mutation detection in the aspartoacylase gene in 17 patients with Canavan disease: four new mutations in the non-Jewish population , 2000, European Journal of Human Genetics.

[106]  D. Bok,et al.  Aspartoacylase deficiency affects early postnatal development of oligodendrocytes and myelination , 2010, Neurobiology of Disease.

[107]  J. Moffett,et al.  N-Acetylaspartate and N-Acetylaspartylglutamate in Central Nervous System Health and Disease , 2014 .